ArticleOncoTargets and therapy2021
Increased Collagen Type V α2 (COL5A2) in Colorectal Cancer is Associated with Poor Prognosis and Tumor Progression.
Article in OncoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 57 citations in OpenAlex.
- Integrative Bulk and Single-Nucleus Analyses Nominate COL5A2 as a CAF/ECM-Associated Marker Associated with PDAC Progression.Diagnostics (Basel, Switzerland) · 2026Article
- Proteomic profiling identifies prognostic signature for Krukenberg tumor of gastrointestinal origin.iScience · 2026Article
- MALDI mass spectrometry imaging of extracellular matrix proteins.The Analyst · 2025Review
- Ion Channel-Extracellular Matrix Interplay in Colorectal Cancer: A Network-Based Approach to Tumor Microenvironment Remodeling.International journal of molecular sciences · 2025Article
- Extracellular matrix: unlocking new avenues in cancer treatment.Biomarker research · 2025Review
- Tumor budding and poorly differentiated clusters as a biological continuum in colorectal cancer invasion and prognosis.Scientific reports · 2025Article
- A molecular network analysis and in silico docking of beta-eudesmol, atractylodin and hinesol in patients with advance stage intrahepatic cholangiocarcinoma.Scientific reports · 2025Article
- The role of various collagen types in tumor biology: a review.Frontiers in oncology · 2025Review
- Glutamate metabotropic receptor 4 in breast cancer: a potential and specific target for chimeric antigen receptor therapy.Frontiers in oncology · 2025Article
- Perineural Invasion Is Associated With Function-evoked Pain and Altered Extracellular Matrix in Patients With Head and Neck Squamous Cell Carcinoma.The journal of pain · 2024Article
- A novel cancer-associated fibroblasts risk score model predict survival and immunotherapy in lung adenocarcinoma.Molecular genetics and genomics : MGG · 2024Article
- Integrated analyses reveal the diagnostic and predictive values of COL5A2 and association with immune environment in Crohn's disease.Genes and immunity · 2024Article
- COL5A2 drives regorafenib resistance-induced metastatic phenotype via reducing LIFR expression in hepatocellular carcinoma.Acta biochimica et biophysica Sinica · 2024Article
- Hic-5 regulates extracellular matrix-associated gene expression and cytokine secretion in cancer associated fibroblasts.Experimental cell research · 2024Article
- RNF185 Control of COL3A1 Expression Limits Prostate Cancer Migration and Metastatic Potential.Molecular cancer research : MCR · 2024Article
- Clinical significance and immune landscape of angiogenesis-related genes in bladder cancer.Aging · 2023Article
- COL5A2 is a prognostic-related biomarker and correlated with immune infiltrates in gastric cancer based on transcriptomics and single-cell RNA sequencing.BMC medical genomics · 2023Article
- Identification of novel prognostic circRNA biomarkers in circRNA-miRNA-mRNA regulatory network in gastric cancer and immune infiltration analysis.BMC genomics · 2023Article
- Review
- Bioinformatics and pathway enrichment analysis identified hub genes and potential biomarker for gastric cancer prognosis.Frontiers in oncology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal cancer (CRC) is the third most common cancer in males and the second in females worldwide with very poor prognosis. Extracellular matrix proteins like collagens play important roles in cancer progression. Collagen type V α2 (COL5A2) is increased in several cancers but its role in cancer remains unclear.
methodsCOL5A2 expression was evaluated by interrogation of public Oncomine gene microarray datasets and immunohistochemistry (IHC) analyses of two tissue microarrays containing 180 paired CRC cases. Survival analysis was performed using Kaplan-Meier survival curve and Cox proportional hazards regression methods. COL5A2 was ectopically expressed in CRC cells, and the cell proliferation was measured using the methylthiazolyldiphenyl-tetrazolium bromide (MTT) method.
results
conclusionCOL5A2 is a potential prognostic marker of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.